102 related articles for article (PubMed ID: 29485044)
1. Associations of Genetic Variations in MicroRNA Seed Regions With Acute Adverse Events and Survival in Patients With Rectal Cancer Receiving Postoperative Chemoradiation Therapy.
Huang Y; Feng Y; Ren H; Zhang M; Li H; Qiao Y; Feng T; Yang J; Wang W; Wang S; Liu Y; Song Y; Li Y; Jin J; Tan W; Lin D
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1026-1033. PubMed ID: 29485044
[TBL] [Abstract][Full Text] [Related]
2. Associations of Genetic Variations in Mismatch Repair Genes MSH3 and PMS1 with Acute Adverse Events and Survival in Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy.
Yang J; Huang Y; Feng Y; Li H; Feng T; Chen J; Yin L; Wang W; Wang S; Liu Y; Song Y; Li Y; Jin J; Tan W; Lin D
Cancer Res Treat; 2019 Jul; 51(3):1198-1206. PubMed ID: 30590005
[TBL] [Abstract][Full Text] [Related]
3. [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Qiao Y; Ren H; Huang Y; DU ZL; Yu DK; Jin J; Li YX; Lin DX; Tan W
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):268-72. PubMed ID: 23985254
[TBL] [Abstract][Full Text] [Related]
4. [Associations of genetic variations in pyroptosis related genes with acute adverse events in postoperative rectal cancer patients receiving concurrent chemoradiotherapy].
Chen HX; Ren NX; Yang J; Chen JN; Lu QX; Feng YR; Huang Y; Yin LL; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):146-152. PubMed ID: 36781235
[No Abstract] [Full Text] [Related]
5. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
[No Abstract] [Full Text] [Related]
6. A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.
Kim SY; Baek JY; Oh JH; Park SC; Sohn DK; Kim MJ; Chang HJ; Kong SY; Kim DY
Radiat Oncol; 2017 Mar; 12(1):62. PubMed ID: 28347333
[TBL] [Abstract][Full Text] [Related]
7. [Genetic variations in apoptosis genes are associated with acute adverse events in postoperative rectal cancer patients receiving concurrent chemoradiotherapy].
Yin LL; Yang J; Feng YR; Huang Y; Feng T; Chen JN; Chen HX; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):376-382. PubMed ID: 32482026
[No Abstract] [Full Text] [Related]
8. Associations of ATM Polymorphisms With Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Receiving Radiation Therapy.
Du Z; Zhang W; Zhou Y; Yu D; Chen X; Chang J; Qiao Y; Zhang M; Huang Y; Wu C; Xiao Z; Tan W; Lin D
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):181-9. PubMed ID: 26094126
[TBL] [Abstract][Full Text] [Related]
9. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
Lin S; Lai H; Qin Y; Chen J; Lin Y
Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
12. Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer.
Dzhugashvili M; Luengo-Gil G; García T; González-Conejero R; Conesa-Zamora P; Escolar PP; Calvo F; Vicente V; Ayala de la Peña F
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):595-602. PubMed ID: 25304949
[TBL] [Abstract][Full Text] [Related]
13. Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Bajetta E; Pietrantonio F; Buzzoni R; Ferrario E; Valvo F; Mariani L; Dotti KF; Biondani P; Formisano B; Gevorgyan A; Grassi P; Di Bartolomeo M
Am J Clin Oncol; 2014 Dec; 37(6):545-9. PubMed ID: 23428953
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
Bohanes P; Rankin CJ; Blanke CD; Winder T; Ulrich CM; Smalley SR; Rich TA; Martensen JA; Benson AB; Mayer RJ; Cripps CM; Danenberg K; Makar KW; Zhang W; Benedetti JK; Lenz HJ
Clin Cancer Res; 2015 Apr; 21(7):1583-90. PubMed ID: 25589620
[TBL] [Abstract][Full Text] [Related]
16. Preoperative long-course chemoradiation for localized rectal cancer: A retrospective comparison of response and outcome between 5-fluorouracil/leucovorin versus capecitabine.
Kunheri B; Gurram B; Madhavan R; Makuny D
Indian J Cancer; 2016; 53(4):518-523. PubMed ID: 28485342
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database.
Garlipp B; Ptok H; Benedix F; Otto R; Popp F; Ridwelski K; Gastinger I; Benckert C; Lippert H; Bruns C
Langenbecks Arch Surg; 2016 Dec; 401(8):1179-1190. PubMed ID: 27830368
[TBL] [Abstract][Full Text] [Related]
18. Oncological outcomes in extended time intervals betweenpreoperative chemoradiotherapy with capecitabine and surgery inoperable rectal adenocarcinoma.
Muñoz MA; Palacios MG; Malca J; Mantilla R; Montenegro PC; Chavez I
Rev Gastroenterol Peru; 2018; 38(1):9-21. PubMed ID: 29791416
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.
Lund JL; Sturmer T; Sanoff HK
J Geriatr Oncol; 2016 May; 7(3):176-86. PubMed ID: 26926829
[TBL] [Abstract][Full Text] [Related]
20. Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
Sastre J; Serrano JJ; Fernández C; Ramirez C; Ortega L; García-Paredes B; Corona J; Alfonso R; Córdoba S; Díaz-Rubio E
Clin Colorectal Cancer; 2016 Jun; 15(2):128-34. PubMed ID: 26385572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
